Coldstream Capital Management Inc. Purchases 231 Shares of Repligen Co. (NASDAQ:RGEN)

Coldstream Capital Management Inc. boosted its position in Repligen Co. (NASDAQ:RGEN) by 11.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,194 shares of the biotechnology company’s stock after purchasing an additional 231 shares during the period. Coldstream Capital Management Inc.’s holdings in Repligen were worth $327,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. Andra AP fonden purchased a new position in Repligen during the 2nd quarter valued at $25,000. International Assets Investment Management LLC bought a new stake in shares of Repligen during the second quarter worth $33,000. UMB Bank n.a. boosted its stake in shares of Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares during the period. Blue Trust Inc. grew its holdings in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares during the last quarter. Finally, Resources Management Corp CT ADV purchased a new position in Repligen in the 3rd quarter worth about $37,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

Shares of RGEN stock opened at $156.41 on Monday. The company has a market cap of $8.76 billion, a P/E ratio of -422.73, a PEG ratio of 4.64 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock’s 50-day moving average is $142.66 and its 200 day moving average is $141.59. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.23 EPS. Research analysts predict that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on RGEN. Wells Fargo & Company began coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Wolfe Research assumed coverage on Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.